Tokai Pharmaceuticals discontinues study By: MarketMinute.com Stock News July 26, 2016 at 18:25 PM EDT Tokai Pharmaceuticals Inc. (Nasdaq: TKAI) will discontinue a late-stage study of its prostate cancer treatment. The stock price collapsed $4.10 to close at $1.10.